Supplementary Figure S4 from Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial
Year: 2026
Type: supplementary-materials
Abstract: Supplementary Figure S4 | Progression-free survival in the efficacy cohort since the initiation of first-line treatment for advanced disease (N = 16). Kaplan-Meier curve from the first-line treatment for metastatic breast cancer with trastuzumab plus pertuzumab plus chemotherapy. CI, confidence interval; NR; not reported; PFS, progression-free survival.
Authors: Mafalda Oliveira, Eva Ciruelos, Guillermo Villacampa, Serafín Morales, Javier Salvador Bofill, Vanesa Quiroga, Joaquín Gavilá, Alexandra Cortegoso, Estela Vega, Fernando Henao, Sonia Servitja, Pablo Tolosa, Samyukta Chillara, Milana Bergamino, Fernando Salvador, Mariana Paes Dias, Juan M. Ferrero-Cafiero, Xavier Gonzalez Farre, Tomás Pascual, Cristina Saura
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7127574841